ADRB2 and asthma: However, a meta-analysis encompassing β2 adrenergic receptor agonist treatment, including salbutamol and the non-selective β-AR agonist isoprenaline, in patients with asthma or COPD indicated a rise in heart rate, with a “non-significant” increase in adverse cardiovascular events such as ventricular tachycardia and sudden death [57].